# Zoetic International consistent increased sales of CHILL, month on month

- Link: https://www.directorstalkinterviews.com/zoetic-international-consistent-increased-sales-of-chill-month-on-month/412861926
- Published: 2020-09-30T08:38:49+01:00
- Author: Amilia Stone

**Zoetic International plc **(LON:ZOE), the London-listed vertically integrated 
CBD company, has announced its unaudited preliminary results for the year ended 
31 March 2020.  The Company’s audited report and accounts for the year ended 31 
March 2020, including all notes to the financial statements, are expected to be 
announced and published later today.

**Period and Post Period Highlights**

·   Transitional year from oil and gas to branded consumer CBD products

·   Establishment of CHILL brand CBD smokes and chew pouches as a leading brand 
in USA

·   Signing of substantial distribution agreements with retail outlets numbering
over 6,000 stores in USA

·   Signing of two international distribution agreements for CHILL delivering coverage
of in excess of 15 countries across Europe

·   Overheads materially reduced and in line with the new consumer CBD products 
business

The key elements of the Company’s results for the year ended 31 March 2020 can be
found below.

**Trading Update**

The directors of the Company are pleased to report that the consumer reaction to
the Company’s CHILL branded products has exceeded their expectations; in stores 
where CHILL has been on sale for several months they have experienced consistent
increased sales, month on month. As the Colorado marketplace has begun to open up
this month from COVID restrictions, the Company’s beta locations have seen a significant
increase in sales.  Chill are now the number one selling non-food CBD products in
the beta stores.  This has been achieved with negligible promotional spend. In the
coming weeks the Company will be officially starting its roll out with its US distribution
partners beyond the beta stores.

The Company is also progressing the logistical processes in order to commence the
international distribution of CHILL products.

The Zoetic brand has also picked up sales momentum.  Online sales have increased
over 300% in the month to date.  Zoetic products are continuing to be shortlisted
for awards, with the most recent being the Top Sante Skincare Awards 2020. The level
of interest around the Zoetic brand is starting to follow the same trajectory of
CHILL. 

The directors will provide further updates to shareholders as the above matters 
progress.

> **Antonio Russo, Co-CEO, commented**: “We couldn’t be more excited for the path
> that the Zoetic branded products are on. It is pleasing to know that consumers
> are loving our products and the awards are flattering as well.”

**Chief Executives’ Review**

The financial year to 31 March 2020 marks the completion of the Group’s most significant
period of change to date. Our debut financial year in the cannabidiol (CBD) sector
has seen the Group evolve from its roots in the natural resources sector and it 
has quickly established itself as a global leader concerned in the development, 
production and distribution of premium CBD products.

Following a managed transition away from the turbulent natural resources market,
the continued growth in popularity of Zoetic’s CBD product range has been complemented
by the founding of key partnerships which continue to facilitate technical excellence
within the fields of research and development. From its inception as a new start
up company under the auspices of Highlands Natural Resources Plc, the US based operating
company Zoetic Corporation, and by extension the renamed parent company Zoetic International
plc, has become a fully-fledged name in its own right, providing a sustainable and
growing profit platform on which to expand.

Despite the challenges 2020 has presented to the global economy, this financial 
year has seen the Group lay the groundwork for an exciting future as a CBD pioneer.
We have now entered the 2020/2021 financial year as an altogether leaner operation
with the technical expertise and international acclaim to bring our products to 
new markets across the globe.

**The Turnaround**

In a year which has seen performance figures collapse for many of the Group’s traditional
competitors, Zoetic has successfully executed a managed exit from the volatile natural
resources sector. Transitioning away from the company’s historical base of activities
was by no means a simple exercise, but it is one that has already borne fruit with
the company benefiting from substantial savings across its asset portfolio. Our 
operational costs are now lower than they have been at any point during the Group’s
history, leaving capital available to reinvest in the continued refinement of our
products.

This movement has been fundamentally driven by the Group’s disposal of its assets
in East Denver and, subsequently, in Kansas. The process commenced with an agreement
to sell the remaining interests in the Group’s oil and gas assets located in Colorado.
Reaching a deal with True Oil LLC which completed in September 2020, the Group has
now neatly tied up its involvement in what was becoming a significant overhead cost
which was not reciprocated by an equivalent rate of return.

Sealing the Group’s substantive exit from the natural resources industry, further
movements came in the form of the proposed divestment of the Group’s Kansas nitrogen
assets to Path Investments PLC (“Path”), a transaction that we expect to close in
the months falling immediately after the publication of this report. As part of 
the transaction, Path has also agreed to purchase the Group’s interest in DT Ultravert(
DTU), its innovative hydrocarbon well stimulation and protection technology. Through
these dealings, the Group launched its efforts to make considerable savings by limiting
its exposure to the continuing high costs of managing and maintaining natural resources
facilities. Our agreement with Path has not only helped us in this endeavour, but
will also secure future liquidity for the Group in the form of 15 million warrants
to subscribe for new ordinary shares in Path at a rate of 0.1 pence each, along 
with warrants for a further 15 million shares at 1.5 pence each to last between 
the first and third anniversaries of the transaction. Perhaps more substantially,
Path has agreed to pay the Group ongoing royalties equating to 6% of all gross revenues
generated from the use of DTU technology, attributable to the 75% interest sold.
In sum, this agreement will grant Zoetic the financial benefit of DTU without the
immoderate overheads that result from the running and management of the project.

Although the completion of this transition falls outside of the period end, it marks
the continued pursuit of a radical new direction for the Group. With the majority
of our natural resources operations having been sold off during August and September
2020, we eliminated the Group’s single largest source of overhead costs and limited
exposure to the risk of further costs over the long term.  As negotiations for the
sale of these assets had commenced but not concluded by the year end, at 31 March
2020 these assets are categorised as “assets held for sale” in the accounts.  Our
exit from the natural resources industry has resulted in the transformation of the
company into a nimble-footed yet formidable contender within the global CBD market.
Free from the need to continually invest in the maintenance of aging oil and gas
facilities, Zoetic has the structural flexibility to act quickly to secure both 
profits and future opportunities alike.

Nowhere has this operational flexibility been more apparent than in the rapidly 
expanding distribution of our various product lines. Eidetic investors may recall
that this financial period was launched with the announcement that an agreement 
had been struck with Schrader Oil and Ox Distributing. The agreement saw our Chill
brand smokes and CBD chew pouches taken to market in convenience stores and gas 
stations across the USA. This landmark agreement was quickly followed by the July
commencement of retail sales in the UK’s expanding CBD market and subsequently the
establishment of a European distribution agreement just a year later. The combined
effect of these developments will see Zoetic’s product range reach markets in the
USA, UK, Czech Republic and Slovakia. Although outside the period, a second international
distribution agreement has now been reached with a highly experienced European retailer
with a strong physical footprint across more than 15 key EU markets and an established
eCommerce presence. As the popularity of our products enjoys continued growth, Zoetic
international’s operations are on course to expand further in the near future. 

**Industry leadership**

As the global CBD market continues to grow, it is Zoetic’s firm intention to establish
itself as an industry leader. The groundwork for this vision has been laid throughout
this financial period and the subsequent months, leaving the Group in a prime position
to continue on its journey as a visionary presence within its field.

Knowing that the value proposition of our products begins with the standard of our
seeds, we have made concerted efforts to test the virility and quality of these 
primary assets. This resulted in the brokering of a landmark partnership with cannabinoid
research experts GVB Biopharma which commenced in July 2020. Complementing our ongoing
research work with a number of renowned US Universities, our programme with GVB 
Biopharma has seen 40,000 feminized hemp seeds placed in the care of their specialists,
who will cultivate the plants in USDA certified ground and gather extensive data
to demonstrate the eminence of our genetic base assets.

The ultimate results of this research will be twofold. Firstly, with the benefit
of scientifically-backed reports into the cultivation viability of our seeds, the
Group will be well placed to avoid the difficulties faced by competitors who have
invested significant time and capital into the cultivation and extraction of genetically
deficient hemp seed stocks. Secondly, the efforts of GVB Biopharma will not only
produce technical resources with which to further the Group’s scientific work but
will also turn out high-calibre CBD isolate. This in turn will furnish the Group
with further resources which can be sent to market as we continue our growth as 
the premium choice in CBD products.

With over 110 varieties of hemp, businesses must meet the specifications set out
by regulatory bodies whilst growing their plants in supervised, quality-controlled
conditions. Having received test results from Colorado State University confirming
a cultivation viability result of between 86% and 95%, we are confident that our
seed genetics will continue to attract agronomical recognition as they undergo further
testing.  By building these operations into the fabric of the Group, we are confident
that Zoetic can continue to grow its involvement across multiple income streams 
both in the recreational and pharmaceutical CBD markets.

In the same vein, and as a critical step towards formalising the Group’s status 
as a market leader, this financial year has seen Zoetic make a range of US Patent
applications which cover the method for the manufacture of Chill brand THC-free 
smokable CBD products and, in an unrelated application, for the composition of pharmaceutical
products which include cannabinoids. Working closely with authoritative figures 
within the scientific community, it is our hope that the coming year will see progression
towards the granting of these patents which offer significant protection to the 
Group’s intellectual property and therefore its position as an innovator at the 
forefront of the CBD industry.

**Product development and diversity**

The growing breadth of Zoetic’s global operations has been mirrored by the continual
expansion of our product range. By extension, our numerous products now provide 
multiple streams of income – the diversity of which provides an essential safeguard
against the regulatory uncertainty faced by companies in the CBD space. 

Sales of products sold under the banner of Chill, Zoetic’s tobacco alternative brand,
have gathered considerable speed in the US market and the Company continues to explore
new ways of meeting consumer demand. Chill’s CBD chew pouches (currently available
in fresh peach, rich vanilla and cool mint flavour variants) have proven to be particularly
popular, and their market share is expected to develop further as we progress through
the next financial period and beyond. Similarly, against a backdrop of strict regulation
within the tobacco market, Chill brand tobacco alternative CBD smokes have enjoyed
enormous popularity with further US distribution agreements already in the pipeline.
Now available in hemp, calm and mint varieties, our smokes continue to benefit from
the regulation of tobacco-based menthol cigarettes which have now been banned in
Brazil, Canada, Ethiopia, Turkey, Moldova, the European Union and the United Kingdom.
With this trend set to continue, Chill brand products stand to become a frontrunner
in the race for a share of the $85 billion strong global menthol cigarette market.
As the Chill range of tobacco alternative products are ready to make their way into
the European arena across the Czech Republic and Slovakia, further emerging markets
are set to follow in the near future as Chill becomes an international name.

Outside of the tobacco alternative market, Zoetic branded goods continue to make
waves across the board. Our range now includes CBD oil, massage oil, vegan gummies,
vegan lip balm, softgels, pills, hand cream, night cream and facial drops. Sold 
across the Group’s core UK market, our Zoetic CBD products each have specific applications
that not only target an area of the market but each aim to become the single most
acclaimed product of their kind. Validating the hard work that has gone into the
creation and marketing of these products, the Group is now the grateful recipient
of numerous awards and nominations that recognise the quality and broad appeal of
our CBD produce. These include:

●     Winner at the Global Green Beauty Awards – Zoetic Jasmine & Lavender CBD Night
Cream

●     Winner at the Hip & Healthy CBD Awards – Zoetic CBD Flavoured Drops range

●    Shortlisted at the Real Beauty Skincare Awards – Zoetic Jasmine & Lavender 
CBD Night Cream

●     Shortlisted for the Marie Claire Skincare Awards –  Zoetic CBD Facial Drops
and Eucalyptus & Lavender CBD Massage Oil

●     Shortlisted for the Pure Beauty London Awards – Zoetic Lemongrass & Ylang 
Ylang CBD Hand Cream and 3000mg Natural CBD Oil

●     Shortlisted for the Top Sante Skin Awards – Zoetic Jasmine & Lavender CBD 
Night Cream

These awards and accolades illustrate almost immediate acclaim for Zoetic and Chill
products upon entry into the market. The calibre of these products speaks for itself
as they have become industry favourites within just months of becoming available.

All of our products, both under the Zoetic and Chill names, are leading the way 
as CBD moves from a recreational novelty into the mainstream. As the popularity 
of traditional tobacco products is hampered by international regulation, it is our
belief that CBD products offer the most viable alternative, whilst our Zoetic gummies,
tinctures, oils and other products allow the health conscious public to access premium
CBD goods. Given estimates that only 6% of the global market currently permits the
development and sale of CBD products, there is huge potential for the growth of 
our sales figures and indeed the Zoetic and Chill brands as political trends point
towards the ongoing deregulation of the cannabidiol industry. 

**Handling the COVID-19 pandemic**

The COVID-19 pandemic has presented issues to companies operating across the world,
and Zoetic has been no exception. The limitations placed on cross-border trade and
movement as a direct response to the pandemic have made it increasingly difficult
to manage the supply chain with the same efficiency as in pre-pandemic times.

Additionally, the necessary restrictions on personnel movements caused by the pandemic
made it impossible for the auditors to attend the stocktake at our UK premises at
the year end.  This has led to the auditors qualifying their audit opinion in this
specific respect.

Throughout these challenging times, the Group has benefitted from its vertically
integrated structure from last harvest year in addition to the extremely strong 
connections it has formed with suppliers, distributors and vendors across the entirety
of its business network. With the ability to make executive decisions with the speed
that modern investors have come to expect, the Group has been able to position itself
as a trendsetter whilst riding out the difficult trading and logistics environment
brought about by the pandemic.

A side effect of the global health emergency has been a renewed level of interest
in holistic health solutions from citizens across the globe. It is our belief that
this environment lends itself to the continued growth in the use of CBD-based products
as medicinal aids, spelling opportunity for the Group across all profit streams 
including Chill as the health-conscious look to turn away from traditional tobacco
products.

**Board changes and operational composition**

The Group’s transition away from it’s legacy assets and into the CBD space has been
supported by the work of it’s joint Chief Executive Officers, Antonio Russo and 
Trevor Taylor. The board’s streamlined nature has allowed the Group to navigate 
the difficulties brought about by the COVID-19 pandemic, given that strategic decisions
can be made with speed and with the benefit of full supply chain oversight. We are
proud of how this structure allows us to grasp opportunities and with the unique
benefit of 15 combined years of experience in the CBD industry, the Board is well
placed to drive growth and further establish the Group as an innovative global presence.

**Listing on the OTC**

In an exciting move for the Group, the year also saw its shares listed on the OTC
market with an opening date of 12 November 2019. This development follows from sustained
interest in the Group from US investors and will better facilitate their ability
to trade in our shares. Owing to the Group’s existing listing on the London Stock
Exchange, obtaining a listing on the OTCQB Venture Market did not require the filing
of a prospectus and moreover there are no    Sarbanes-Oxley or SEC reporting requirements
or disclosure obligations beyond those already met for the purposes of the London
listing. 

**CBD facilities**

In line with the Zoetic’s substantive efforts to cut costs and restructure its activities,
this year has also seen the termination of the Group’s leasehold agreement for its
Colorado greenhouse facility. This follows a significant period of growth for our
CBD products and it is now the case that our resources requirements can be focused
on our product lines.

Moving forward, cultivation and production of our high-quality base seed assets 
will be entrusted to a European partner based in the UK. Having brokered a Joint
Venture agreement (the “JV”) with one of Europe’s best regarded cultivation specialists,
we now look forward to the next stage of growth as we benefit from their knowledge
and expertise in the fields of growth and regulation. Closing the doors to our original
facility has also enabled the Company to make a significant saving by eliminating
one of its most substantial overhead costs totalling some $80,000 per month in operational
spending.

**Outlook**

As mentioned at the outset of this review, this financial year has been one of extensive
yet positive change for the Group as Zoetic has come to the fore of its operations.
What last year was described as a ‘foothold’ in an exciting growth industry has 
now given way to the establishment of a growing global brand that has achieved early
acclaim for its quality and innovation.

Despite a tumultuous year for the global economy, the Group is now fighting fit 
and in a state of continual growth that we strongly believe will persist as we move
through the 2020/2021 period. With numerous international level distribution agreements
and penetration of the lucrative eCommerce market, our business continues to gain
ground in the international CBD arena which itself is ever expanding despite robust
regulation. The breadth of Zoetic’s CBD operations means shareholders can take heart
that our revenues are somewhat guarded against changes within the market and we 
expect our seed and retail operations to escalate further throughout the current
financial year, both in terms of activity and revenues.

We have now arrived at a seminal point in the Group’s development. Since the launch
of Zoetic in 2019, it has been the intention of the Board to follow a four pronged
strategy to secure the very best future for its CBD business interests. Throughout
the course of the financial period and in the months since, huge ground has been
made towards the realisation of these goals, and the contents of this report along
with Group’s wider operations serve to show that we have developed products that
fit the market and have mass appeal. Furthermore, with the announcement of numerous
International Distribution Agreements, along with a new cultivation Joint Venture
in the UK, the Board is confident that the Group now benefits from veritable scalability
and distribution channels on a multinational scale. Throughout the next financial
period we will continue to build on these elements, but also crucially will execute
a full product launch with our products making it to market across multiple territories,
many for the first time. In turn, we expect this to have a positive resultant impact
on our sales revenues and the Group will of course continue to benefit from the 
cost-cutting exercise conducted during the 2019/2020 financial period.

This is an exciting time for the Group, and we would like to extend our thanks to
our shareholders who have made this transformative phase possible. As we now look
to accelerate out of the turnaround, this financial year holds great promise and
we have every confidence that Zoetic will continue to make waves across the fast
developing CBD industry.

Antonio Russo

Trevor Taylor

Joint Chief Executives

30 September 2020

**Financial Review**

During the year the Group has seen its primary source of revenue generation shift
from the sale of oil and gas and it now sits firmly in the sale of its CBD products.
Although a loss was made on the eventual disposal of the Group’s legacy natural 
resources assets, which were classified as assets held for sale at the year end,
this movement has allowed for a significant reduction in ongoing costs.

**Key developments**

The Group’s year began with the formal launch of Zoetic Corporation as a wholly-
owned subsidiary of Highlands Natural Resources plc (“Highlands”). The Group’s CBD
arm quickly saw commercial growth as it entered into a retail distribution and sales
agreement in April 2019, facilitating the sale of its CBD smokables and CBD chew
pouches. The period since has seen the activities of the operating entity,  Zoetic
Corporation, expand and this laid the foundation for the relaunch of the parent 
company as Zoetic International plc.

Following this development, further retail distribution and sales agreements have
been reached with partners in the UK, the Czech Republic, Slovakia and in other 
key European markets. Online sales have also commenced during the period, both of
the eponymous Zoetic range of products and of Chill branded CBD tobacco alternative
products. As the Group scales up its retail output, sales revenues from its various
products are expected to grow whilst the costs of production have been limited through
establishment of a strategic joint venture with a UK-based cultivation expert. The
Group’s operations in this sphere are in a growth phase and so substantial revenues
were not expected during the year.  

This financial year and the subsequent months saw the Group attempt to divest itself
of its legacy natural resources assets. This followed the continual decline of revenues
from its oil and gas producing wells, along with difficulty in monetising its rights
and assets in other fields.

Most significantly, a buyer was found for the Group’s 5% interest in eight oil and
gas producing wells in East Denver. Whilst the asset was sold at a loss, its disposal
will have a substantial positive impact on the Group’s future operational costs.
It is also of note that the disposal of the Group’s East Denver assets has allowed
it to settle an outstanding loan of bank loan of US $276,574 from ANB Bank. A potential
buyer has also been identified for the Group’s interest in a nitrogen production
well situated in Kansas, along with its 75% stake in the patents for the DT Ultravert
well protection technology. The consequence of the Group’s disposal of its interests
in the legacy Kansas and DT Ultravert assets has not yet been finalised but the 
deal is expected to return a combination of shares, options, and a continuing royalty
of 6% for the use of the DT Ultravert patents. This transaction is expected to conclude
in the month following the publication of this review.

Ultimately the year has seen the Group make a loss after taxation of £7,078,513,
however this figure does not fully reflect the transition undergone throughout the
period. Through its divestment of non-performing and under-performing natural resource
assets, the Group has made substantial savings whilst limiting its exposure to ongoing
costs and further risk from volatility within the oil and gas market. 

**Funding**

As raised in last year’s Financial Review, the Group has funded its CBD operations
to date through a fundraising effort in March 2019 which raised £1.56 million before
costs.

During this financial period the Group raised £1.66 million net of costs from the
exercise of warrants and the issue of shares. This included a fundraising effort
in February 2020 which saw the Group raise £387,000 through a subscription for £
330,000 of convertible loan notes and 950,000 ordinary shares of 1 pence each at
a price of 6 pence per Ordinary Share.

In the weeks following the end of the period, the Group successfully applied for
loans under the US COVID-19 aid arrangements to the approximate value of $290,000(
approximately £230,000). The majority of this funding will meet the requirements
necessary for the borrowing to be forgiven, whilst any residual sum shall be repayable
over a period of two years with an annual interest rate of 1%. 

**Revenue**

The Group’s revenue has fallen from the 2019 figures, and this decline can in part
be attributed to the partial cessation of the Group’s involvement in the natural
resources industry along with the global deterioration of oil and gas prices. The
Group is no longer generating revenue from its remaining legacy natural resources
assets and future revenue generation will centre around its interests in the CBD
industry.

**Expenditure**

The year has been characterised by a significant cost-cutting exercise, the effects
of which are likely to become more obvious as the next financial year goes on. This
includes, most notably, the cessation of costs relating to legacy natural resources
assets, the management of DT Ultravert, and the closure of the Group’s hemp growth
facility in Colorado. These efforts are expected to see a reduction in costs in 
excess of US$1 million.

The Group’s main costs are now its ongoing cultivation, development and production
of CBD products, along with costs relating to distribution and external professional
fees both in the US and in London where the Company bears the costs associated with
its listing on the London Stock Exchange, including legal, regulatory and public
relation costs.

**Liquidity, cash and cash equivalents**

At the year end the Group held approximately £349,000 at the bank. Moving forward,
it is expected that the Group’s CBD business will begin to be cash positive in the
short term, with strong revenues expected to follow in the near term as its Zoetic
and Chill retail brands grow their market share

**Events after the reporting period**

The end of the reporting period coincided with the rapid spread of the COVID-19 
novel coronavirus which has played some part in the drastic deterioration of global
oil and gas prices. This saw a reduction in the operating output of the Group’s 
natural resource production facilities and a resultant decline in associated revenues.
The following months saw the Group secure ‘COVID-19’ loans in the US in the value
of $290,000, most of which will meet the requirements to be forgiven. Any residual
sum will be repayable over two years and will attract interest of 1% per annum.

On 3 April 2020, the Group issued a further 12,900,000 ordinary shares of 1 pence
each to the now Joint Chief Executive Officers, Antonio Russo and Trevor Taylor.
This issue followed an incentive arrangement entered into with the new management
team during March 2019.

Following the establishment of the Group’s cannabidiol (“CBD”) business, various
distribution agreements have now been reached in respect of the Chill and Zoetic
retail brands under which the Group’s CBD goods are sold. These include a multi-
state distribution agreement with BettermentRS in the US, a further agreement for
the distribution of Chill brand tobacco alternative CBD products across the Czech
Republic and Slovakia, and an additional EU-focussed international distribution 
agreement involving 15 distinct European markets. In addition to these agreements,
the Group has entered into a new arrangement with a UK-based partner for the cultivation
of feminized hemp seeds and the local distribution of its CBD products. This agreement
follows the conclusion of the Group’s Joint Venture with former CEO Mr Nick Tulloch.

The months following the end of the reporting period have also seen the progression
of the Group’s managed exit from the natural resources sector. May 2020 saw an asset
purchase agreement reached between the Group and Path Investments plc, the latter
of which will acquire the Group’s 75% interest in the patented hydrocarbon well 
stimulation and protection technology, DT Ultravert. The agreement also saw Path
Investments plc acquire the Group’s Kansas nitrogen assets, along with all associated
leases and equipment. As a result of the aforementioned agreement, the Group will
receive 15 million warrants to subscribe for new ordinary shares in Path at a rate
of 0.1 pence each, along with warrants for a further 15 million shares at 1.5 pence
each to last between the first and third anniversaries of the transaction. Path 
has agreed to pay, in perpetuity, to Zoetic a royalty equal to 6% of all gross revenues
received by Path that are derived from DTU and attributable to the 75% interest 
being sold, accruing from receipt of first revenues although not payable until 12
months thereafter.

In September 2020, the Group reached an agreement regarding the disposal of its 
East Denver oil and has assets to the operator of those facilities, True Oil LLC.
The proceeds of sale from the East Denver assets was agreed at US$376,000, although
the Group had a loan secured on the assets of US$276,574 from ANB Bank. Following
the execution of this agreement, the ANB Bank loan has been settled in full and 
the Company now has no borrowings. In the same month the Group finalised the closure
of the legacy Highlands Natural Resources Corporation office in Denver, Colorado,
along with the termination of a number of employment and consultancy contracts for
personnel concerned with the management of the Group’s former natural resources 
assets. Zoetic International’s Colorado-based hemp cultivation and CBD production
centre has also been closed, generating a saving of some $80,000 per month. Growing
operations continue with research partners and will also recommence on a commercial
level in the UK.

Share on:
